‘Tajani’ Initiative

Over Breakfast, the discussion focused on updates on Commissioner Tajani’s CSR Initiative for pharmaceuticals, with a particular focus on the access to medicines in Africa pillar, intellectual  property rights and capacity building.

The Q& A session touched upon topics such as

  • OTC Working Group
  • Revision of the Transparency Directive (expected to be published by the Commission on 7 March)
  • EC’s Regulatory Dialogues with third countries
  • Regulatory environment in emerging markets
  • R&D competitiveness of the EU
  • Patient access to new medicines
  • Minimum requirements for successful agreements
  • Neglected diseases
  • Sustainable healthcare budget

Speaker: Thomas Heynisch, Acting Head of Unit, Food and Healthcare Industries, Biotechnology, DG ENTR

Topic: ‘Tajani’ Initiative: Corporate responsibility for the pharmaceutical industry

Supported by the Health, Consumer & Social Affairs – 14th February 2012


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: